REDWOOD CITY, Calif., April 17 /PRNewswire/ -- Ingenuity Systems, the leading provider of information solutions for the exploration, interpretation, and analysis of experimental data for life sciences researchers, today introduced Ingenuity Pathways Analysis 5.0, the first software of its kind to offer specific functions for identifying biomarker candidates and characterizing molecular toxicity in a biological context. IPA-Biomarker(TM) and IPA-Tox(TM), within the IPA application, enable researchers to mechanistically connect biomarkers to pathways of disease and drug response, and elucidate toxic effects not revealed by traditional methods. In addition to these capabilities, IPA 5.0 contains an extensive addition of new expert- extracted content from the scientific literature, including new knowledge about diseases, exogenous and endogenous chemicals, and drugs and clinical candidates.
“There is a substantive need for researchers to understand and examine their data in a biological framework,” commented Walter Darbonne, Associate Scientist, Pharmacodynamic Biomarkers, Oncology at Genentech. “As many of us know, most companies have invested a large number of resources in acquiring technologies that generate vast quantities of data but researchers are still unclear on how to translate discoveries made with those technologies into safe and effective drugs. With IPA 5.0, we were able to quickly and easily identify molecular biomarkers in our dataset, connect them to mechanisms of disease or drug response, and then check where those proteins have been detected, for example in blood, urine, or the sentinel tissue blood. This is a huge advancement.”
Ingenuity Pathways Analysis 5.0 is a software application that enables researchers to model, analyze, and understand the complex biological and chemical systems at the core of life science research. IPA is deployed in all major pharmaceutical companies and in hundreds of biotechnology companies and academic institutions globally. It supports analysis of data from all experimental platforms, and is used at all stages of the drug discovery and development process, including target identification and validation, identification of biomarkers, predictive toxicology, and pharmacogenomics.
New Features of IPA 5.0 IPA-Biomarker(TM): A New Biomarker Solution within IPA 5.0 IPA-Biomarker is designed to: -- Identify and prioritize the most promising biomarker candidates from datasets -- Prioritize molecular biomarker candidates based on key biological characteristics -- Perform analysis across biomarker lists to find biomarker candidates unique to a disease stage or common across all stages -- Elucidate mechanisms linking potential markers to a disease or biological process of interest -- Understand the molecular differences between patient populations IPA-Tox(TM): A New Molecular Toxicity Solution within IPA 5.0 IPA-Tox is designed to: -- Assess the toxicity and safety of compounds of interest early in the development process -- Provide expert molecular toxicology data interpretation to non- expert users -- Reveal clinical pathology endpoints associated with a dataset -- Generate new hypotheses that may not have been revealed using traditional toxicology approaches -- Elucidate mechanism of toxicity and identify potential markers of toxicity -- Easily access important findings from the scientific literature, including information associated with cardiovascular toxicity, nephrotoxicity, and hepatotoxicity Improved Tools for Biological Interpretation and Communication -- Upload data without the need for file templates -- Review analysis summaries for quick, broad overviews -- Send interactive network and pathway diagrams to colleagues -- Create high quality pathway diagrams for publications and presentations
Increased Expert-Extracted Content
IPA 5.0 has also been updated to incorporate a large quantity of new expert-extracted biological and chemical information from the scientific literature.
“One of the features that makes IPA such a successful and distinctive product is the unrivaled breadth, depth, and consistency of the content,” commented Ramon Felciano, Chief Technology Officer of Ingenuity Systems. “When developing IPA 5.0, we expanded and updated the content to include additional information on toxicity, the central nervous system, and messenger RNA. For our toxicology solution, we have included information about thousands of compounds, including endogenous chemicals and metabolites, FDA approved drugs and clinical candidates, and exogenous chemicals and toxicants. This is a great example of our ongoing commitment to maintain IPA’s extensive repository of biological and chemical knowledge and ultimately support our customers and their research efforts.”
Trials of Ingenuity Pathways Analysis 5.0 are currently being offered at http://www.ingenuity.com/trial. For more information about Ingenuity Pathways Analysis 5.0, please email sales@ingenuity.com or go to www.ingenuity.com
About Ingenuity Systems(R)
Ingenuity enables researchers to model, analyze, and understand complex biological and chemical systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for life scientists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotech companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan. www.ingenuity.com.
Ingenuity Systems
CONTACT: Holli Dickson, Account Supervisor of Porter Novelli LifeSciences, +1-619-849-5380, or hdickson@pnlifesciences.com; or HeidiBullock, Director, Marketing of Ingenuity Systems, +1-650-381-5150
Web site: http://www.ingenuity.com//
